证券代码：300109 证券简称：新开源 公告编号：2023-085 博爱新开源医疗科技集团股份有限公司 关于对外投资暨增资北京良远生物医药研究有限公司的 公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次对外投资概述 1、交易基本情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司""新开源"）拟 与北京良远生物医药研究有限公司（以下简称"良远生物"或"标的公司"）及 其股东北京良远科技发展中心（有限合伙）（以下简称"良远科技"）、北京良 远健康科技中心（有限合伙）（以下简称"良远健康"）、北京荷塘生命科学原 始创新基金（有限合伙）、北京荷慧生物科技合伙企业（有限合伙）、北京诺善 同创投资管理中心（有限合伙）签署《关于北京良远生物医药研究有限公司之增 资协议》（以下简称"《增资协议》"），约定公司以增资的方式向良远生物投 资人民币 5000.00 万元，用于认缴良远生物新增注册资本 44.6429 万元，剩余部 分计入其资本公积。本次增资完成后，公司将持有良远生物 23.81%的股权。 2、审议情况 2023 年 8 月 28 日，公司第五 ...

本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： （一）博爱新开源医疗科技集团股份有限公司（以下简称"公司"）已于 2023 年 6 月 26 日召开 2023 年第三次临时股东大会，审议通过《关于回购注销 2021 年限制性股票激励计划部分限制性股票的议案》，决定回购注销 2021 年限制性 股票激励计划（以下简称"本激励计划"）已授予但尚未解除限售的部分限制性 股票： 1、本激励计划首次授予的激励对象中，10 名激励对象因个人原因已离职、 3 名激励对象已退休且未继续在公司任职、2 名激励对象因换届选举担任公司监 事、6 名激励对象因个人绩效考核未达标或未完全达标，由公司回购注销相关限 制性股票共计 115.20 万股，回购价格为 4.96 元/股，公司已以货币资金方式支付 回购价款人民币 5,713,920.00 元，资金来源为公司自有资金。 2、本激励计划预留授予的激励对象中，4 名激励对象因个人绩效考核未达 标或未完全达标，由公司回购注销相关限制性股票共计 15.15 万股，回购价格为 9.02 元/股，公司已以货币资金方式支付回购价款人民 ...

证券代码： 300109 证券简称：新开源 博爱新开源医疗科技集团股份有限公司 投资者关系活动记录表 编号：2023-0711 投资者关系活动 □特定对象调研 □分析师会议 类别 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 生命保险资产管理有限公司 李燕玲 人员姓名 中信建投证券股份有限公司 柳强 南方基金管理股份有限公司 郑勇 国泰君安证券 肖洁、李旋坤、陈传双 博道基金管理有限公司 王伟淼 上海钦沐资产管理合伙企业（有限合伙） 赵一鸣 深圳市康叶生命资产管理有限公司 周志超 国泰基金管理有限公司 钱晓杰 浙江圣熙资产管理有限公司 张皓博 重庆市金科投资控股（集团）有限责任公司 李翌 上海兆天投资管理有限公司 於震騋 歌斐资产管理有限公司 周烨 华泰保兴基金管理有限公司 礼晨 贵州中企联创私募基金管理有限公司 翁鼎 申万宏源证券资产管理有限公司 梁飚 时间 2023 年 7 月 11 日 地点 网络 上市公司接待人 员姓名 董事会秘书 邢小亮 1.公司上半年业绩情况 回复：公司上半年取得归母净利润 2.5 亿元-2.7 亿元， 扣非净利润 ...

证券代码： 300109 证券简称：新开源 编号：2023-0611 投资者关系活动 ☑特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 中融基金管理有限公司 朱晓明 人员姓名 深圳市康叶生命资产管理有限公司 周志超 歌斐资产管理有限公司 周烨 国泰君安证券 钟浩、钱伟伦、李旋坤、陈寒梅、陈传双 上海钦沐资产管理合伙企业（有限合伙） 赵一鸣 北京鸿道投资管理有限责任公司 张亚男 恒识投资管理（上海）有限公司 张熙、 刘文可、杜亮 西安蓝晓科技新材料股份有限公司 张辉 前海人寿保险股份有限公司 姚尧 博时基金管理有限公司 肖瑞瑾 上海道申投资管理有限公司 王琦 广发基金管理有限公司 王丽媛 中国银河证券股份有限公司 王恺 摩根士丹利基金管理（中国）有限公司 孙人杰 上海秋晟资产管理有限公司 钮舒越 中信建投证券股份有限公司 柳强 中化石油销售有限公司 林晨 申万宏源证券资产管理有限公司 梁飚 重庆市金科投资控股（集团）有限责任公司 李翌 博爱新开源医疗科技集团股份有限公司 投资者关系活动记录表 | --- | - ...

证券代码： 300109 证券简称：新开源 博爱新开源医疗科技集团股份有限公司 投资者关系活动记录表 编号：2023-0612 投资者关系活动 特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 信达澳亚基金管理有限公司 伏涛、王明浩、尹燕潇 人员姓名 博睿乾远基金 余卓远、李博闻 招商证券 曹承安 国泰君安 杨一帆、王涛涛 时间 2023 年 6 月 12 日 地点 新开源焦作本部 董事长 张军政 上市公司接待人 董事会秘书 邢小亮 员姓名 一、公司多媒体展厅参观 二、公司管理层座谈交流 交流内容： 1.PVP 产品的主要应用领域。 PVP 在传统应用领域、新兴领域均有广泛应用。 投资者关系活动 传统应用领域：主要为医药、日化、食品等； 主要内容介绍 新兴领域：主要为新能源行业等 在医药领域：主要作为片剂粘合剂、包衣片、缓释剂、崩 解剂、增溶作用等；日化领域：化妆品成膜剂、日化产品杀菌 剂、口腔处理去污剂、漂白剂、洗涤用品活性剂等。食品领域： 酿酒、饮料中的澄清剂和稳定剂。 | --- | |---------- ...

证券代码：300109 证券简称：新开源 公告编号：2023-062 博爱新开源医疗科技集团股份有限公司 关于参加河南辖区上市公司 2023 年投资者网上 集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，博爱新开源医疗科技集团股份有限公司 （以下简称"公司"）定于 2023 年 5 月 18 日（周四）16:00-17:20 参加在全景 网举办的"真诚沟通 传递价值"河南辖区上市公司 2023 年投资者网上集体接待 日活动，本次活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （ http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员有：公司董事长张军政先生、董事会秘 书邢小亮先生、财务总监刘爱民先生，欢迎广大投资者积极参与。 特此公告 博爱新开源医疗科技集团股份有限公司 董事会 2023 年 5 月 12 日 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[66]. - The company’s operating revenue for 2022 was CNY 1,485,693,905, representing a 21.75% increase compared to CNY 1,220,275,240 in 2021[23]. - The net profit attributable to shareholders of the listed company for 2022 was CNY 291,463,635, a 40.77% increase from CNY 207,047,711 in 2021[23]. - The company reported a total revenue of 3,783.06 million for the year 2022[51]. - The company achieved a gross margin of 45%, up from 40% in the previous year, due to cost optimization measures[15]. - The company reported a significant increase in non-recurring gains and losses, with a net profit of CNY 316,554,577.34 in 2022, compared to CNY 10,191,272.43 in 2021, marking a 2,965.93% increase[23]. - The company reported a total revenue of 127,854.8 million CNY for the year, with a net profit of 41,712.38 million CNY, indicating a strong financial performance[131]. - The company reported a significant increase in revenue, reaching 1.2 billion CNY in 2022, representing a year-over-year growth of 15%[71]. - The company reported a total revenue of 52,558,047 in 2021, indicating a significant growth trajectory[60]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[15]. - The company is focused on expanding its market presence in Southeast Asia, targeting a 10% market share by 2025[53]. - The company is exploring market expansion opportunities in both domestic and international markets to increase its footprint[54]. - The company is actively pursuing market expansion, targeting both domestic and international markets to increase its footprint in the dental care sector[57]. - The company is exploring potential mergers and acquisitions to strengthen its market position[134]. - The company is exploring strategic opportunities for market expansion and potential mergers or acquisitions to bolster its growth trajectory[180]. - The company is focusing on expanding its product offerings in the renewable energy sector, responding to increasing demand and orders in this area[180]. Research and Development - Investment in R&D increased by 30%, focusing on new technologies in molecular diagnostics and precision medicine[15]. - The company has a mature and effective R&D system, with increased investment in R&D and recruitment of skilled personnel, leading to improved product quality and cost-effectiveness[48]. - The company is committed to enhancing its research and development capabilities to drive innovation in medical technology[51]. - The company has invested 100 million CNY in R&D for new technologies and product development in 2023[72]. - The company is investing in research and development of innovative medical technologies and solutions[135]. - The company has invested in advanced research and development, focusing on innovative dental care solutions to meet evolving consumer needs[57]. - The company is focusing on R&D and aligning products with market demand to navigate economic uncertainties and promote high-quality development[177]. Product Development and Innovation - The company is set to launch three new products in the next quarter, which are anticipated to contribute an additional 200 million RMB in revenue[15]. - New product developments are underway, focusing on innovative medical technologies aimed at enhancing patient care[54]. - The company is focusing on the development of new products, including next-generation DNA sequencing and genetic testing services[133]. - The company is actively developing new medical devices and instruments, including dental equipment and surgical implants, to enhance its product offerings[59]. - The company is focusing on the development of new products and technologies, particularly in the PVP sector, to enhance market competitiveness[181]. - The company has completed the development of a high-efficiency method for analyzing sample methylation levels, which enhances operational efficiency and expands business scope[112]. - The company has developed a new preservation solution for COVID-19 virus sampling, ensuring the accuracy of virus extraction and testing results[108]. Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, ensuring accountability from its executives[3]. - The report highlights the company's commitment to compliance with regulatory standards and quality management practices[12]. - The company has obtained various quality certifications, including the Drug Production License and GMP certification, ensuring compliance with quality management standards[49]. - The company is committed to strict compliance with national regulations to mitigate operational risks associated with policy changes[176]. Operational Efficiency - The company aims to enhance its operational efficiency and maximize asset utilization across its properties[51]. - The company aims to reduce operational costs by 15% through improved efficiency measures[53]. - The company is committed to enhancing its operational performance through resource integration and improved efficiency to reduce goodwill impairment risks[176]. - The company is focusing on improving the quality of its products through advanced production techniques, aligning with international standards such as USP, EP, and JP[107]. User Engagement and Customer Satisfaction - User data showed an increase in active users, reaching 2 million, which is a 15% increase year-over-year[15]. - Customer satisfaction ratings improved to 90%, reflecting the effectiveness of recent service enhancements[53]. - User data indicates a growing customer base, with a 20% increase in active users compared to the previous year, totaling approximately 500,000 users[76]. - User data indicates a growing demand for dental care products, with an increasing trend in consumer awareness regarding oral hygiene[56]. Risks and Challenges - The company faces significant risks from national policy changes in the healthcare sector, which could adversely affect operational performance if strategies are not adjusted accordingly[176]. - Rising labor costs are a concern as employee numbers and compensation levels increase; if revenue does not grow correspondingly, this could negatively affect future performance[176]. - The company reported a non-recurring loss of 19 million yuan in the first half of the year, which needs to be addressed to improve financial health[179]. Intellectual Property - The company holds multiple trademarks, including "博爱新开源" and "WHIVIDONE," with registration numbers ranging from 5418542 to 13675232, valid until 2029 and beyond[55]. - The company has established a strong intellectual property portfolio, which is essential for competitive advantage in the healthcare and consumer goods markets[55]. - The company has secured a total of 20 patents, with a mix of invention and utility model patents, showcasing its commitment to enhancing its technological capabilities[62]. Sustainability and Ethical Practices - The company is committed to sustainability and is exploring eco-friendly product options to meet consumer demand[58]. - A commitment to sustainability and ethical practices is being prioritized in the company's long-term strategy[54].

Financial Performance - The company's revenue for Q1 2023 was ¥363,003,583.47, representing a 16.77% increase compared to ¥310,869,875.29 in the same period last year[4] - Net profit attributable to shareholders reached ¥119,979,801.13, a significant increase of 267.98% from ¥32,604,859.37 year-on-year[4] - Basic earnings per share increased to ¥0.39, up 290.00% from ¥0.10 in the same quarter last year[4] - Operating profit significantly improved to ¥154,728,205.01, up from ¥44,095,556.29, marking an increase of 250.5%[27] - Net profit for the current period was ¥119,313,647.55, compared to ¥31,554,115.42 in the previous period, reflecting a growth of 278.5%[27] - The company reported a total comprehensive income of ¥119,468,991.30, compared to ¥31,741,429.97 in the previous period, an increase of 276.5%[28] Cash Flow - The net cash flow from operating activities was ¥104,812,243.03, a 159.99% improvement from a negative cash flow of ¥174,723,246.02 in the previous year[4] - Cash inflow from operating activities totaled ¥357,576,096.52, slightly down from ¥360,232,183.38 in the previous period[30] - The company reported a total cash outflow of ¥73,643,622.61 for the quarter, compared to a cash outflow of ¥363,589,918.13 in the previous year[31] - Total cash outflow from investing activities was ¥181,329,902.33, compared to ¥48,915,893.14 in the same period last year, resulting in a net cash flow from investing activities of -¥180,410,623.98[31] - Cash inflow from financing activities amounted to ¥6,500,000.00, an increase from ¥2,039,500.00 in Q1 2022, leading to a net cash flow from financing activities of ¥3,702,270.27[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,793,407,270.55, reflecting a 2.15% increase from ¥3,713,523,107.73 at the end of the previous year[4] - The total liabilities decreased from 596,286,950.89 yuan at the beginning of the year to 557,069,733.15 yuan[25] - The company's total equity increased from 3,117,236,156.84 yuan to 3,236,337,537.40 yuan[25] - The company held long-term equity investments valued at 114,691,584.83 yuan, up from 14,393,865.83 yuan at the beginning of the year[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 16.232 million[13] - The largest shareholder, Wang Donghu, holds 8.66% of shares, amounting to 28,063,481 shares, with 22,441,972 shares pledged[13] - Wang Jianqiang, the second-largest shareholder, owns 4.86% of shares, totaling 15,731,091 shares, with 8,274,390 shares pledged[13] - The top ten shareholders include various institutional investors, with the largest being CITIC Securities and Wuhu Great Wall Guolong Investment Management Co., holding 3.95% and 3.91% respectively[13] - The total number of restricted shares at the beginning of the period was 56,497,025, with 14,095,217 shares released during the period[17] Strategic Initiatives - The company is actively managing its shareholder structure, with a focus on maintaining control among key stakeholders[14] - The report indicates a strategic focus on retaining key executives through share lock-up agreements[17] - The company is preparing for future growth by ensuring a stable shareholder base and aligning interests with management through equity incentives[18] - The company acquired a 13% stake in Suzhou Dongsheng Xingye Scientific Instrument Co., Ltd. for 5.2 million yuan through its wholly-owned subsidiary Changsha Sanji Biotechnology Co., Ltd.[19] - The company granted 3 million restricted shares to its chief scientist Herbert Wilhelm Ulmer at a price of 1.00 yuan per share as part of its 2023 restricted stock incentive plan[19] Operational Efficiency - The company's cash flow from operating activities showed a positive trend, indicating improved operational efficiency compared to the previous year[31] - Financial expenses decreased by 77.27% to -¥1,281,367.91, attributed to a reduction in interest income[10] - Research and development expenses increased to ¥11,097,533.95 from ¥10,738,557.48, showing a rise of 3.4%[27] - Other income increased by 295.35% to ¥3,157,658.46, mainly due to an increase in government subsidies related to production operations[10] - The company experienced a foreign exchange loss of ¥1,747,511.93 during the quarter[31]